Primary care perspectives on prescribing anti‐obesity medication for adolescents
Pediatric Obesity · 2024-08 · 19 (8)
DOI: 10.1111/ijpo.13146 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pediatric Obesity, online erschienen am 16.06.2024. Verfasst von Rutha Chivate und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA. Hauptthemen laut MEDLINE: Pediatric Obesity, Anti-Obesity Agents, Practice Patterns, Physicians', Primary Health Care. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIDDK NIH HHS, NIH HHS, NICHD NIH HHS.
Abstract (Originalsprache)
Background
Recent pediatric guidelines recommend clinicians offer anti‐obesity medication (AOM) as an adjunct to intensive lifestyle intervention.
Objective
To investigate pediatricians' perspectives about prescribing AOM, including barriers and facilitators.
Methods
An investigator‐developed survey was emailed to primary care pediatric physicians ( n = 187) and advanced practice providers ( n = 190) within an academic‐affiliated network. The survey evaluated how willing clinicians were to prescribe AOM and their agreement with 25 statements about barriers and facilitators. Three vignettes explored AOM decision‐making. Multinomial logistic regression was used to determine relative risk ratios for willingness to prescribe by agreement with each statement.
Results
Among 74 respondents (20% response rate), 24% were willing, 42% uncertain and 34% unwilling to prescribe. Most (64%) agreed that AOM should be managed only by specialists. Willingness to prescribe was associated with clinician motivation and belief in guideline practicality and applicability. Unwillingness was associated with beliefs that patients would not continue AOM long enough for benefit and that there was insufficient time or resources to implement. In vignettes, 52% were willing to prescribe AOM for a patient with severe obesity and metabolic complications, versus 11% for a patient with obesity and possible disordered eating.
Conclusions
Willingness to prescribe AOM was low and was associated with perceived practicality and appropriateness for patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA.
- UPMC Children's Community Pediatrics, Pittsburgh, Pennsylvania, USA.
- Division of General Academic Pediatrics, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
- Center for Pediatric Obesity Medicine, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
- Division of Pediatric Endocrinology and Diabetes, University of Minnesota Medical School, Minneapolis, Minnesota, USA.
- Division of Pediatric Endocrinology, Diabetes, and Metabolism, Center for Pediatric Research in Obesity and Metabolism, UPMC Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania, USA.
ORCID-Profile: Rutha Chivate, Pamela Schoemer, Megan O Bensignor
Förderung
- NIDDK NIH HHS
- NIH HHS
- NICHD NIH HHS
- National Institutes of Health
Zitieren
APA
Chivate, R., Schoemer, P., Ragavan, M. I., Ray, K., Bensignor, M. O., Goldschmidt, A. B., & Vajravelu, M. E. (2024). Primary care perspectives on prescribing anti‐obesity medication for adolescents. Pediatric Obesity, 19(8). https://doi.org/10.1111/ijpo.13146
Vancouver
Chivate R, Schoemer P, Ragavan MI, Ray K, Bensignor MO, Goldschmidt AB, et al. Primary care perspectives on prescribing anti‐obesity medication for adolescents. Pediatric Obesity. 2024;19(8). doi:10.1111/ijpo.13146
BibTeX
@article{Chivate2024,
author = {Chivate, Rutha and Schoemer, Pamela and Ragavan, Maya I and Ray, Kristin and Bensignor, Megan O and Goldschmidt, Andrea B and Vajravelu, Mary Ellen},
title = {Primary care perspectives on prescribing anti‐obesity medication for adolescents},
journal = {Pediatric Obesity},
year = {2024},
volume = {19},
number = {8},
doi = {10.1111/ijpo.13146}
}
EUVIMED